FL Sarasota의 난소암 임상 시험
난소암 관련 연구 16개가 Sarasota 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
피험자 모집 중관찰 연구
- Sarasota Memorial Health Care System, Sarasota
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
피험자 모집 중1/2상
- Florida Cancer Specialists, Sarasota
Study of AVZO-021 in Patients With Advanced Solid Tumors
피험자 모집 중1/2상
- Avenzo Therapeutics Recruiting Site, Sarasota
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
피험자 모집 중1/2상
- Florida Cancer Specialists, Sarasota
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
피험자 모집 중3상
- Sarasota Memorial Health Care System, Sarasota
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
피험자 모집 중3상
- Sarasota Memorial Health Care System, Sarasota
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
피험자 모집 중3상
- Sarasota Memorial Hospital ( Site 0075), Sarasota
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
피험자 모집 중3상
- Sarasota Memorial Healthcare System, Sarasota
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
피험자 모집 중1상
- SCRI - Florida Cancer Specialists, Sarasota
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
피험자 모집 중
- Florida Cancer Specialists - Sarasota, Sarasota
- Intercoastal Medical Group - Cattleridge II, Sarasota
- First Physicians Group - Gastroenterology Obesity Medicine, Sarasota
- 외 7개
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
피험자 모집 중1/2상
- Florida Cancer Specialists, Sarasota
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
피험자 모집 중1상
- Florida Cancer Specialists & Research Institute, Sarasota
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
피험자 모집 중1/2상
- Florida Cancer Specialists, Sarasota
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
피험자 모집 중2상
- First Physicians Group /ID# 272180, Sarasota
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
피험자 모집 중1상
- Florida Cancer Specialists, Sarasota
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
피험자 모집 중1상
- Dren Investigational Site, Sarasota
다른 도시의 난소암 시험
- Houston, TX연구 89개
- New York City, NY연구 69개
- Boston, MA연구 61개
- Los Angeles, CA연구 50개
- Nashville, TN연구 49개
- Arlington, VA연구 46개
- Philadelphia, PA연구 44개
- Columbus, OH연구 39개
- St. Louis, MO연구 38개
- Chicago, IL연구 36개
- San Antonio, TX연구 31개
- Cleveland, OH연구 30개
Sarasota의 다른 연구
- 전이성 암연구 19개
- 비소세포폐암연구 17개
- 대장직장암연구 16개
- 자궁내막암연구 14개
- 유방암연구 12개
- 암 (전체)연구 11개
- 삼중음성 유방암연구 8개
- 폐암연구 7개
- 췌장암연구 7개
- 심방세동연구 7개
- 전립선암연구 6개
- 지방간질환연구 6개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.